News

Deal Announcements

Clarus Therapeutics Clears Third Round Funding

Wednesday, November 28, 2007 5:45:00 AM PDT | VentureDeal Staff
NORTHBROOK, IL -- Biotech company Clarus Therapeutics, Inc. said that it has closed its series C financing round and received $8 million for the purpose of supported its Phase II trials of its oral testosterone drug.

While there are other testosterone treatments on the market, they are delivered by injection or IV, resulting in a less optimal patient compliance.  The company believes the market for a convenient orally-delivered treatment is significant.

Investors in the round were H.I.G. Ventures and Thomas, McNerny & Partners.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1